Grifols (GRFS) Cash from Operations (2010 - 2020)
Grifols (GRFS) reported Cash from Operations of 116320951.13 for Q1 2020, up 161.02% on a YoY basis from 44564177.7 in Q2 2019, and down 69.02% quarter-over-quarter from 375465153.7 in Q4 2019.
Grifols (GRFS) Cash from Operations (2010 - 2020) Analysis & Trends
Grifols has reported Cash from Operations for 10 years, with the latest figure at 116320951.13 in Q1 2020.
- For the quarter ending Q1 2020, Cash from Operations rose 161.02% year-over-year to 116320951.13; the trailing twelve-month figure through Mar 2020 stood at 767696482.23 (up 33.15% YoY), and the FY2025 full-year result was 1218753559.89, up 26.44% from the prior year.
- Cash from Operations for Q1 2020 stood at 116320951.13, down from 375465153.7 in the prior quarter.
- The five-year high for Cash from Operations was 671810029.36 in Q4 2017, with the low at 190630846.21 in Q1 2019.
- Historically, Cash from Operations has averaged 234197285.45 across 5 years, with a median of 194784409.05 in 2016.
- Annual changes were most pronounced in 2017 — Cash from Operations soared 244.9% — and 2019, when it plunged 267.38%.
- Grifols' Cash from Operations stood at 194784409.05 in 2016, then soared by 244.9% to 671810029.36 in 2017, then plunged by 30.55% to 466541223.61 in 2018, then decreased by 19.52% to 375465153.7 in 2019, then tumbled by 69.02% to 116320951.13 in 2020.
- The last three Cash from Operations figures came in at 116320951.13 (Q1 2020), 375465153.7 (Q4 2019), and 190630846.21 (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 116.32 Mn |
| Mar 31, 2020 | 116.32 Mn |
| Dec 31, 2019 | 375.47 Mn |
| Dec 31, 2019 | 375.47 Mn |
| Mar 31, 2019 | -190.63 Mn |
| Mar 31, 2019 | -190.63 Mn |
| Dec 31, 2018 | 466.54 Mn |
| Dec 31, 2018 | 466.54 Mn |
| Jun 30, 2018 | 186.75 Mn |
| Jun 30, 2018 | 186.75 Mn |
| Mar 31, 2018 | 113.89 Mn |
| Mar 31, 2018 | 113.89 Mn |
| Dec 31, 2017 | 671.81 Mn |
| Dec 31, 2017 | 671.81 Mn |
| Jun 30, 2017 | 256.39 Mn |
| Jun 30, 2017 | 256.39 Mn |
| Mar 31, 2017 | 154.89 Mn |
| Mar 31, 2017 | 154.89 Mn |
| Dec 31, 2016 | 194.78 Mn |
| Dec 31, 2016 | 194.78 Mn |